Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 52

1.

How to optimize HCV therapy in genotype 1 patients: predictors of response.

Petta S, Craxì A.

Liver Int. 2013 Feb;33 Suppl 1:23-9. doi: 10.1111/liv.12053. Review.

PMID:
23286842
2.

How to optimize HCV therapy in genotype 1 patients with cirrhosis.

Bourlière M, Wendt A, Fontaine H, Hézode C, Pol S, Bronowicki JP.

Liver Int. 2013 Feb;33 Suppl 1:46-55. doi: 10.1111/liv.12067. Review.

PMID:
23286846
3.

Pre-treatment prediction of response to pegylated-interferon plus ribavirin for chronic hepatitis C using genetic polymorphism in IL28B and viral factors.

Kurosaki M, Tanaka Y, Nishida N, Sakamoto N, Enomoto N, Honda M, Sugiyama M, Matsuura K, Sugauchi F, Asahina Y, Nakagawa M, Watanabe M, Sakamoto M, Maekawa S, Sakai A, Kaneko S, Ito K, Masaki N, Tokunaga K, Izumi N, Mizokami M.

J Hepatol. 2011 Mar;54(3):439-48. doi: 10.1016/j.jhep.2010.07.037. Epub 2010 Sep 19.

PMID:
21129805
4.

Interleukin 28B genetic polymorphisms play a minor role in identifying optimal treatment duration in HCV genotype 1 slow responders to pegylated interferon plus ribavirin.

Liu CH, Liang CC, Liu CJ, Tseng TC, Lin CL, Yang SS, Su TH, Lin JW, Chen JH, Chen PJ, Chen DS, Kao JH.

Antivir Ther. 2012;17(6):1059-67. doi: 10.3851/IMP2322. Epub 2012 Aug 17.

PMID:
22898703
5.

Boceprevir and telaprevir-based triple therapy for chronic hepatitis C: virological efficacy and impact on kidney function and model for end-stage liver disease score.

Virlogeux V, Pradat P, Bailly F, Funingana G, Gonçalves F, Maynard M, Hartig-Lavie K, Amiri M, Zoulim F.

J Viral Hepat. 2014;21(9):e98-e107. doi: 10.1111/jvh.12237. Epub 2014 Feb 25.

PMID:
24612466
6.

Predictors of response to chronic hepatitis C treatment.

Moraes Coelho HS, Villela-Nogueira CA.

Ann Hepatol. 2010;9 Suppl:54-60.

PMID:
20713997
7.

IL28B polymorphisms predict the response to chronic hepatitis C virus infection treatment in a Mexican population.

Martínez-Gómez LE, Chávez-Tapia NC, Burguete-García AI, Aguilar-Olivos N, Madrid-Marina V, Román-Bahena M, Orbe-Orihuela C, Misael U, Méndez-Sánchez N.

Ann Hepatol. 2012 Nov-Dec;11(6):876-81.

8.

Cost-effectiveness of boceprevir or telaprevir for untreated patients with genotype 1 chronic hepatitis C.

Cammà C, Petta S, Enea M, Bruno R, Bronte F, Capursi V, Cicchetti A, Colombo GL, Di Marco V, Gasbarrini A, Craxì A; WEF Study Group.

Hepatology. 2012 Sep;56(3):850-60. doi: 10.1002/hep.25734. Epub 2012 Jul 12.

PMID:
22454336
9.

Cost-effectiveness of boceprevir or telaprevir for previously treated patients with genotype 1 chronic hepatitis C.

Cammà C, Petta S, Cabibbo G, Ruggeri M, Enea M, Bruno R, Capursi V, Gasbarrini A, Alberti A, Craxì A; WEF Study Group.

J Hepatol. 2013 Oct;59(4):658-66. doi: 10.1016/j.jhep.2013.05.019. Epub 2013 May 23.

PMID:
23707373
10.

Treatment of chronic hepatitis C in Asia: when East meets West.

Yu ML, Chuang WL.

J Gastroenterol Hepatol. 2009 Mar;24(3):336-45. doi: 10.1111/j.1440-1746.2009.05789.x. Review.

PMID:
19335784
11.

IL28B polymorphism is associated with treatment response in patients with genotype 4 chronic hepatitis C.

Asselah T, De Muynck S, Broët P, Masliah-Planchon J, Blanluet M, Bièche I, Lapalus M, Martinot-Peignoux M, Lada O, Estrabaud E, Zhang Q, El Ray A, Vidaud D, Ripault MP, Boyer N, Bedossa P, Valla D, Vidaud M, Marcellin P.

J Hepatol. 2012 Mar;56(3):527-32. doi: 10.1016/j.jhep.2011.09.008. Epub 2011 Sep 25.

PMID:
21951981
12.

Effectiveness and safety of first-generation protease inhibitors in clinical practice: Hepatitis C virus patients with advanced fibrosis.

Salmerón J, Vinaixa C, Berenguer R, Pascasio JM, Sánchez Ruano JJ, Serra MÁ, Gila A, Diago M, Romero-Gómez M, Navarro JM, Testillano M, Fernández C, Espinosa D, Carmona I, Pons JA, Jorquera F, Rodriguez FJ, Pérez R, Montero JL, Granados R, Fernández M, Martín AB, Muñoz de Rueda P, Quiles R; Alhambra Spanish Study Group.

World J Gastroenterol. 2015 Aug 14;21(30):9163-74. doi: 10.3748/wjg.v21.i30.9163.

13.

Interleukin-28B genetic variants in identification of hepatitis C virus genotype 1 patients responding to 24 weeks peginterferon/ribavirin.

Huang CF, Huang JF, Yang JF, Hsieh MY, Lin ZY, Chen SC, Wang LY, Juo SH, Chen KC, Chuang WL, Kuo HT, Dai CY, Yu ML.

J Hepatol. 2012 Jan;56(1):34-40. doi: 10.1016/j.jhep.2011.03.029. Epub 2011 May 19. Erratum in: J Hepatol. 2012 May;56(5):1218.

PMID:
21703176
14.

Triple therapy with boceprevir or telaprevir for prior HCV non-responders.

Asselah T.

Best Pract Res Clin Gastroenterol. 2012 Aug;26(4):455-62. doi: 10.1016/j.bpg.2012.09.003.

PMID:
23199504
15.

Effect of IL28B genotype on early viral kinetics during interferon-free treatment of patients with chronic hepatitis C.

Chu TW, Kulkarni R, Gane EJ, Roberts SK, Stedman C, Angus PW, Ritchie B, Lu XY, Ipe D, Lopatin U, Germer S, Iglesias VA, Elston R, Smith PF, Shulman NS.

Gastroenterology. 2012 Apr;142(4):790-5. doi: 10.1053/j.gastro.2011.12.057. Epub 2012 Jan 13.

PMID:
22248659
16.

Association of IL28B genotype and viral response of hepatitis C virus genotype 2 to interferon plus ribavirin combination therapy.

Akuta N, Suzuki F, Seko Y, Kawamura Y, Sezaki H, Suzuki Y, Hosaka T, Kobayashi M, Kobayashi M, Saitoh S, Arase Y, Ikeda K, Kumada H.

J Med Virol. 2012 Oct;84(10):1593-9. doi: 10.1002/jmv.23368.

PMID:
22930507
17.

Interleukin-28B polymorphisms on the SVR in the treatment of naïve chronic hepatitis C with pegylated interferon-α plus ribavirin: a meta-analysis.

Shi KQ, Liu WY, Lin XF, Fan YC, Chen YP, Zheng MH.

Gene. 2012 Oct 1;507(1):27-35. doi: 10.1016/j.gene.2012.07.026. Epub 2012 Jul 25.

PMID:
22842190
18.

IL28B genetic polymorphism testing in the era of direct acting antivirals therapy for chronic hepatitis C: ten years too late?

Jensen DM, Pol S.

Liver Int. 2012 Feb;32 Suppl 1:74-8. doi: 10.1111/j.1478-3231.2011.02712.x. Review.

PMID:
22212576
19.

Predictive value of the IL28B polymorphism on the effect of interferon therapy in chronic hepatitis C patients with genotypes 2a and 2b.

Kawaoka T, Hayes CN, Ohishi W, Ochi H, Maekawa T, Abe H, Tsuge M, Mitsui F, Hiraga N, Imamura M, Takahashi S, Kubo M, Tsunoda T, Nakamura Y, Kumada H, Chayama K.

J Hepatol. 2011 Mar;54(3):408-14. doi: 10.1016/j.jhep.2010.07.032. Epub 2010 Sep 19.

PMID:
21112660
20.

Importance of IL28B gene polymorphisms in hepatitis C virus genotype 2 and 3 infected patients.

Sarrazin C, Susser S, Doehring A, Lange CM, Müller T, Schlecker C, Herrmann E, Lötsch J, Berg T.

J Hepatol. 2011 Mar;54(3):415-21. doi: 10.1016/j.jhep.2010.07.041. Epub 2010 Sep 22.

PMID:
21112657

Supplemental Content

Support Center